The Patient Protection and Affordable Care Act's rationing of health care: Implications for dermatology - 16/10/14
Funding sources: The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories LP. |
|
Disclosure: Dr Feldman is a consultant and speaker for Galderma, Stiefel/GlaxoSmithKline, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, Biogen Idec, and Bristol Myers Squibb. Dr Feldman has received grants from Galderma, Astellas, Abbott Labs, Warner Chilcott, Janssen, Amgen, Photomedex, Genentech, Biogen Idec, Coria/Valeant, Pharmaderm, Ortho Pharmaceuticals, Aventis Pharmaceuticals, Roche Dermatology, 3M, Bristol-Myers Squibb, Stiefel/GlaxoSmithKline, Novartis, Medicis, Leo, HanAll Pharmaceuticals, Celgene, Basilea, and Anacor, and has received stock options from Photomedex. He is owner of www.drscore.com and a founder of Causa Research. The other authors declared no conflicts of interest. |
Vol 71 - N° 5
P. 998-999 - novembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?